Search

Your search keyword '"Gaggar, Anuj"' showing total 506 results
Start Over Author "Gaggar, Anuj"
506 results on '"Gaggar, Anuj"'

1. Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation

Author

Xu, Zhi Ming, Gnouamozi, Gnimah Eva, Rüeger, Sina, Shea, Patrick R., Buti, Maria, Chan, Henry LY., Marcellin, Patrick, Lawless, Dylan, Naret, Olivier, Zeller, Matthias, Schneuing, Arne, Scheck, Andreas, Junier, Thomas, Moradpour, Darius, Podlaha, Ondrej, Suri, Vithika, Gaggar, Anuj, Subramanian, Mani, Correia, Bruno, Gfeller, David, Urban, Stephan, and Fellay, Jacques

Published
2024
Full Text
View/download PDF

3. Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection

Author

Janssen, Harry L., Lim, Young-Suk, Kim, Hyung Joon, Sowah, Leonard, Tseng, Cheng-Hao, Coffin, Carla S., Elkhashab, Magdy, Ahn, Sang Hoon, Nguyen, Anh-Hoa, Chen, Diana, Wallin, Jeffrey J., Fletcher, Simon P., McDonald, Circe, Yang, Jenny C., Gaggar, Anuj, Brainard, Diana M., Fung, Scott, Kim, Yoon Jun, Kao, Jia-Horng, Chuang, Wan-Long, Brooks, Anna E., and Dunbar, P. Rod

Published
2024
Full Text
View/download PDF

4. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells

Author

Aggarwal, Abhishek, Odorizzi, Pamela M., Brodbeck, Jens, van Buuren, Nicholas, Moon, Christina, Chang, Silvia, Adona, MaryVic, Suthram, Silpa, Suri, Vithika, Trowe, Torsten, Turner, Scott, Marcellin, Patrick, Buti, Maria, Gaggar, Anuj, Fletcher, Simon P., Diehl, Lauri, Feierbach, Becket, and Balsitis, Scott

Published
2023
Full Text
View/download PDF

5. Compassionate Use of Remdesivir for Patients with Severe Covid-19

Author

Grein, Jonathan, Ohmagari, Norio, Shin, Daniel, Diaz, George, Asperges, Erika, Castagna, Antonella, Feldt, Torsten, Green, Gary, Green, Margaret L, Lescure, François-Xavier, Nicastri, Emanuele, Oda, Rentaro, Yo, Kikuo, Quiros-Roldan, Eugenia, Studemeister, Alex, Redinski, John, Ahmed, Seema, Bernett, Jorge, Chelliah, Daniel, Chen, Danny, Chihara, Shingo, Cohen, Stuart H, Cunningham, Jennifer, D'Arminio Monforte, Antonella, Ismail, Saad, Kato, Hideaki, Lapadula, Giuseppe, L'Her, Erwan, Maeno, Toshitaka, Majumder, Sumit, Massari, Marco, Mora-Rillo, Marta, Mutoh, Yoshikazu, Nguyen, Duc, Verweij, Ewa, Zoufaly, Alexander, Osinusi, Anu O, DeZure, Adam, Zhao, Yang, Zhong, Lijie, Chokkalingam, Anand, Elboudwarej, Emon, Telep, Laura, Timbs, Leighann, Henne, Ilana, Sellers, Scott, Cao, Huyen, Tan, Susanna K, Winterbourne, Lucinda, Desai, Polly, Mera, Robertino, Gaggar, Anuj, Myers, Robert P, Brainard, Diana M, Childs, Richard, and Flanigan, Timothy

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Emerging Infectious Diseases, Lung, Clinical Trials and Supportive Activities, Clinical Research, Prevention, Infectious Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adenosine Monophosphate, Administration, Intravenous, Adult, Aged, Aged, 80 and over, Alanine, Antiviral Agents, Betacoronavirus, COVID-19, Canada, Compassionate Use Trials, Coronavirus Infections, Europe, Female, Humans, Japan, Male, Middle Aged, Pandemics, Pneumonia, Viral, Respiration, Artificial, SARS-CoV-2, United States, Young Adult, COVID-19 Drug Treatment, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundRemdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.MethodsWe provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day.ResultsOf the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.ConclusionsIn this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.).

Published
2020

7. Nomenclature of HBV core protein-targeting antivirals

Author

Zoulim, Fabien, Zlotnick, Adam, Buchholz, Stephanie, Donaldson, Eric, Fry, John, Gaggar, Anuj, Hu, Jianming, Kann, Michael, Lenz, Oliver, Lin, Kai, Mani, Nagraj, Nassal, Michael, Delaney, William, Wang, Su, Westman, Gabriel, Miller, Veronica, and Janssen, Harry L. A.

Published
2022
Full Text
View/download PDF

10. Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection

Author

van Buuren, Nicholas, Ramirez, Ricardo, Turner, Scott, Chen, Diana, Suri, Vithika, Aggarwal, Abhishek, Moon, Christina, Kim, Sam, Kornyeyev, Dmytro, Bui, Nam, Bhardwaj, Neeru, Chan, Henry LY, Marcellin, Patrick, Buti, Maria, Wallin, Jeffrey, Gaggar, Anuj, Fletcher, Simon P., Diehl, Lauri, Li, Li, Mo, Hongmei, and Feierbach, Becket

Published
2022
Full Text
View/download PDF

11. An OX40/OX40L interaction directs successful immunity to hepatitis B virus

Author

Publicover, Jean, Gaggar, Anuj, Jespersen, Jillian M, Halac, Ugur, Johnson, Audra J, Goodsell, Amanda, Avanesyan, Lia, Nishimura, Stephen L, Holdorf, Meghan, Mansfield, Keith G, Judge, Joyce Bousquet, Koshti, Arya, Croft, Michael, Wakil, Adil E, Rosenthal, Philip, Pai, Eric, Cooper, Stewart, and Baron, Jody L

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Liver Disease, Hepatitis, Chronic Liver Disease and Cirrhosis, Hepatitis - B, Digestive Diseases, Infectious Diseases, Aetiology, 2.1 Biological and endogenous factors, Infection, Inflammatory and immune system, Good Health and Well Being, Animals, Hepatitis B virus, Hepatitis B, Chronic, Immunity, Innate, Mice, Mice, Knockout, OX40 Ligand, Receptors, OX40, Biological Sciences, Medical and Health Sciences, Medical biotechnology, Biomedical engineering
Abstract

Depending on age of acquisition, hepatitis B virus (HBV) can induce a cell-mediated immune response that results in either cure or progressive liver injury. In adult-acquired infection, HBV antigens are usually cleared, whereas in infancy-acquired infection, they persist. Individuals infected during infancy therefore represent the majority of patients chronically infected with HBV (CHB). A therapy that can promote viral antigen clearance in most CHB patients has not been developed and would represent a major health care advance and cost mitigator. Using an age-dependent mouse model of HBV clearance and persistence in conjunction with human blood and liver tissue, we studied mechanisms of viral clearance to identify new therapeutic targets. We demonstrate that age-dependent expression of the costimulatory molecule OX40 ligand (OX40L) by hepatic innate immune cells is pivotal in determining HBV immunity, and that treatment with OX40 agonists leads to improved HBV antigen clearance in young mice, as well as increased strength of T cell responses in young mice and adult mice that were exposed to HBV when they were young and developed a CHB serological profile. Similarly, in humans, we show that hepatic OX40L transcript expression is age-dependent and that increased OX40 expression on peripheral CD4+ T cells in adults is associated with HBV clearance. These findings provide new mechanistic understanding of the immune pathways and cells necessary for HBV immunity and identify potential therapeutic targets for resolving CHB.

Published
2018

12. Virus-associated Inflammation Imprints an Inflammatory Profile on Long-lived Monocyte-derived Macrophages in the Human Liver

Author

Sanchez Vasquez, Juan Diego, primary, Nkongolo, Shirin, additional, Traum, Daniel, additional, Kim, Samuel C., additional, Mahamed, Deeqa, additional, Mehrotra, Aman, additional, Patel, Anjali, additional, Chen, Diana, additional, Fung, Scott, additional, Gaggar, Anuj, additional, Feld, Jordan J., additional, Chang, Kyong-Mi, additional, Wallin, Jeffrey J., additional, Janssen, Harry L.A., additional, and Gehring, Adam J., additional

Published
2024
Full Text
View/download PDF

13. Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic [CD8.sup.+] T cells

Author

Nkongolo, Shirin, Mahamed, Deeqa, Kuipery, Adrian, Vasquez, Juan D. Sanchez, Kim, Samuel C., Mehrotra, Aman, Patel, Anjali, Hu, Christine, McGilvray, Ian, Feld, Jordan J., Fung, Scott, Chen, Diana, Wallin, Jeffrey J., Gaggar, Anuj, Janssen, Harry L.A., and Gehring, Adam J.

Subjects
CD8 lymphocytes -- Health aspects, Cell death -- Health aspects, Antiviral agents -- Patient outcomes, Hepatitis B -- Drug therapy -- Development and progression -- Patient outcomes, Health care industry
Abstract

Accumulation of activated immune cells results in nonspecific hepatocyte killing in chronic hepatitis B (CHB), leading to fibrosis and cirrhosis. This study aims to understand the underlying mechanisms in humans and to define whether these are driven by widespread activation or a subpopulation of immune cells. We enrolled CHB patients with active liver damage to receive antiviral therapy and performed longitudinal liver sampling using fine-needle aspiration to investigate mechanisms of CHB pathogenesis in the human liver. Single-cell sequencing of total liver cells revealed a distinct liver-resident, polyclonal [CD8.sup.+] T cell population that was enriched at baseline and displayed a highly activated immune signature during liver damage. Cytokine combinations, identified by in silico prediction of ligand-receptor interaction, induced the activated phenotype in healthy liver [CD8.sup.+] T cells, resulting in nonspecific Fas ligand-mediated killing of target cells. These results define a [CD8.sup.+] T cell population in the human liver that can drive pathogenesis and a key pathway involved in their function in CHB patients., Introduction Nonspecific activation of memory [CD8.sup.+] T cells is a common feature of acute and chronic human viral diseases (1-7). Bystander-activated [CD8.sup.+] T cells respond in a TCR-independent manner and [...]

Published
2023
Full Text
View/download PDF

15. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

Author

Lampertico, Pietro, Buti, Maria, Fung, Scott, Ahn, Sang Hoon, Chuang, Wan-Long, Tak, Won Young, Ramji, Alnoor, Chen, Chi-Yi, Tam, Edward, Bae, Ho, Ma, Xiaoli, Flaherty, John F, Gaggar, Anuj, Lau, Audrey, Liu, Yang, Wu, George, Suri, Vithika, Tan, Susanna K, Subramanian, G Mani, Trinh, Huy, Yoon, Seung-Kew, Agarwal, Kosh, Lim, Young-Suk, and Chan, Henry L Y

Published
2020
Full Text
View/download PDF

19. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection

Author

Cheng, Xiaoming, Uchida, Takuro, Xia, Yuchen, Umarova, Regina, Liu, Chun-Jen, Chen, Pei-Jer, Gaggar, Anuj, Suri, Vithika, Mucke, Marcus M., Vermehren, Johannes, Zeuzem, Stefan, Teraoka, Yuji, Osawa, Mitsutaka, Aikata, Hiroshi, Tsuji, Keiji, Mori, Nami, Hige, Shuhei, Karino, Yoshiyasu, Imamura, Michio, Chayama, Kazuaki, and Liang, T. Jake

Subjects
United States. Food and Drug Administration, Sofosbuvir -- Health aspects, Backup software -- Health aspects, Biological response modifiers -- Health aspects, Medical research -- Health aspects, Infection -- Health aspects, Hepatitis C virus -- Health aspects, Interferon -- Health aspects, Comorbidity -- Health aspects, Hepatitis B -- Health aspects, Backup software, Health care industry
Abstract

In patients with HBV and HCV coinfection, HBV reactivation leading to severe hepatitis has been reported with the use of direct-acting antivirals (DAAs) to treat HCV infection. Here we studied the molecular mechanisms behind this viral interaction. In coinfected cell culture and humanized mice, HBV replication was suppressed by HCV coinfection. In vitro, HBV suppression was attenuated when interferon (IFN) signaling was blocked. In vivo, HBV viremia, after initial suppression by HCV superinfection, rebounded following HCV clearance by DAA treatment that was accompanied by a reduced hepatic IFN response. Using blood samples of coinfected patients, IFN-stimulated gene products including C-X-C motif chemokine 10 (CXCL10), C-C motif chemokine ligand 5 (CCL5), and alanine aminotransferase (ALT) were identified to have predictive value for HBV reactivation after HCV clearance. Taken together, our data suggest that HBV reactivation is a result of diminished hepatic IFN response following HCV clearance and identify serologic markers that can predict HBV reactivation in DAA-treated HBV-HCV-coinfected persons., Introduction Hepatitis B virus (HBV) and hepatitis C virus (HCV) together infect more than 300 million people worldwide. Due to the shared modes of transmission and epidemiological features, they frequently [...]

Published
2020
Full Text
View/download PDF

22. Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

Author

Sulkowski, Mark S, Naggie, Susanna, Lalezari, Jacob, Fessel, Walford Jeffrey, Mounzer, Karam, Shuhart, Margaret, Luetkemeyer, Anne F, Asmuth, David, Gaggar, Anuj, Ni, Liyun, Svarovskaia, Evguenia, Brainard, Diana M, Symonds, William T, Subramanian, G Mani, McHutchison, John G, Rodriguez-Torres, Maribel, and Dieterich, Douglas

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Emerging Infectious Diseases, Liver Disease, Clinical Research, Digestive Diseases, Hepatitis - C, Genetics, Clinical Trials and Supportive Activities, HIV/AIDS, Infectious Diseases, Hepatitis, Chronic Liver Disease and Cirrhosis, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Administration, Oral, Adult, Aged, Antiviral Agents, Coinfection, Drug Administration Schedule, Drug Therapy, Combination, Female, Genotype, HIV Infections, Hepacivirus, Hepatitis C, Humans, Male, Middle Aged, RNA, Viral, Ribavirin, Sofosbuvir, Treatment Outcome, Uridine Monophosphate, Viral Load, Young Adult, PHOTON-1 Investigators, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

ImportanceTreatment of hepatitis C virus (HCV) infection in patients also infected with human immunodeficiency virus (HIV) has been limited due to drug interactions with antiretroviral therapies (ARTs) and the need to use interferon.ObjectiveTo determine the rates of HCV eradication (sustained virologic response [SVR]) and adverse events in patients with HCV-HIV coinfection receiving sofosbuvir and ribavirin treatment.Design, setting, and participantsOpen-label, nonrandomized, uncontrolled phase 3 trial conducted at 34 treatment centers in the United States and Puerto Rico (August 2012-November 2013) evaluating treatment with sofosbuvir and ribavirin among patients with HCV genotypes 1, 2, or 3 and concurrent HIV. Patients were required to be receiving ART with HIV RNA values of 50 copies/mL or less and a CD4 T-cell count of more than 200 cells/μL or to have untreated HIV infection with a CD4 T-cell count of more than 500 cells/μL. Of the treatment-naive patients, 114 had HCV genotype 1 and 68 had HCV genotype 2 or 3, and 41 treatment experienced participants who had been treated with peginterferon-ribavirin had HCV genotype 2 or 3, for a total of 223 participants.InterventionsTreatment-naive patients with HCV genotype 2 or 3 received 400 mg of sofosbuvir and weight-based ribavirin for 12 weeks and treatment-naive patients with HCV genotype 1 and treatment-experienced patients with HCV genotype 2 or 3 received the same treatment for 24 weeks.Main outcomes and measuresThe primary study outcome was the proportion of patients with SVR (serum HCV

Published
2014

23. TLR7 Agonist Increases Responses of Hepatitis B Virus–Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues

Author

Boni, Carolina, Vecchi, Andrea, Rossi, Marzia, Laccabue, Diletta, Giuberti, Tiziana, Alfieri, Arianna, Lampertico, Pietro, Grossi, Glenda, Facchetti, Floriana, Brunetto, Maurizia R., Coco, Barbara, Cavallone, Daniela, Mangia, Alessandra, Santoro, Rosanna, Piazzolla, Valeria, Lau, Audrey, Gaggar, Anuj, Subramanian, G. Mani, and Ferrari, Carlo

Published
2018
Full Text
View/download PDF

24. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B

Author

Publicover, Jean, Gaggar, Anuj, Nishimura, Stephen, Van Horn, Christine M, Goodsell, Amanda, Muench, Marcus O, Reinhardt, R Lee, van Rooijen, Nico, Wakil, Adil E, Peters, Marion, Cyster, Jason G, Erle, David J, Rosenthal, Philip, Cooper, Stewart, and Baron, Jody L

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Digestive Diseases, Hepatitis - B, Chronic Liver Disease and Cirrhosis, Vaccine Related, Hepatitis, Infectious Diseases, Immunization, Liver Disease, 2.1 Biological and endogenous factors, Infection, Inflammatory and immune system, Good Health and Well Being, Adult, Age Factors, Animals, Chemokine CXCL13, Disease Resistance, Hepatitis B virus, Hepatitis B, Chronic, Humans, Immunity, Innate, Infant, Interleukins, Liver, Lymphoid Tissue, Macrophages, Mice, Mice, Inbred C57BL, Mice, Knockout, Oligonucleotide Array Sequence Analysis, Receptors, CXCR5, Spleen, Transcriptome, Medical and Health Sciences, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Hepatitis B virus (HBV) is a major human pathogen that causes immune-mediated hepatitis. Successful immunity to HBV is age dependent: viral clearance occurs in most adults, whereas neonates and young children usually develop chronic infection. Using a mouse model of HBV infection, we sought mechanisms underpinning the age-dependent outcome of HBV and demonstrated that hepatic macrophages facilitate lymphoid organization and immune priming within the adult liver and promote successful immunity. In contrast, lymphoid organization and immune priming was greatly diminished in the livers of young mice, and of macrophage-depleted adult mice, leading to abrogated HBV immunity. Furthermore, we found that CXCL13, which is involved in B lymphocyte trafficking and lymphoid architecture and development, is expressed in an age-dependent manner in both adult mouse and human hepatic macrophages and plays an integral role in facilitating an effective immune response against HBV. Taken together, these results identify some of the immunological mechanisms necessary for effective control of HBV.

Published
2013

26. Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro.

Author

Rossi, Marzia, Vecchi, Andrea, Tiezzi, Camilla, Barili, Valeria, Fisicaro, Paola, Penna, Amalia, Montali, Ilaria, Daffis, Stephane, Fletcher, Simon P., Gaggar, Anuj, Medley, Jonathan, Graupe, Michael, Lad, Latesh, Loglio, Alessandro, Soffredini, Roberta, Borghi, Marta, Pollicino, Teresa, Musolino, Cristina, Alfieri, Arianna, and Brillo, Federica

Subjects
HEPATITIS B vaccines, T cells, ALANINE aminotransferase, CHRONIC hepatitis B, CD8 antigen, MONONUCLEAR leukocytes, T-cell exhaustion, HEPATITIS B
Published
2023
Full Text
View/download PDF

28. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Author

Buti, Maria, Gane, Edward, Seto, Wai Kay, Chan, Henry L Y, Chuang, Wan-Long, Stepanova, Tatjana, Hui, Aric-Josun, Lim, Young-Suk, Mehta, Rajiv, Janssen, Harry L A, Acharya, Subrat K, Flaherty, John F, Massetto, Benedetta, Cathcart, Andrea L, Kim, Kyungpil, Gaggar, Anuj, Subramanian, G Mani, McHutchison, John G, Pan, Calvin Q, Brunetto, Maurizia, Izumi, Namiki, and Marcellin, Patrick

Published
2016
Full Text
View/download PDF

29. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Author

Chan, Henry L Y, Fung, Scott, Seto, Wai Kay, Chuang, Wan-Long, Chen, Chi-Yi, Kim, Hyung Joon, Hui, Aric Josun, Janssen, Harry L A, Chowdhury, Abhijit, Tsang, Tak Yin Owen, Mehta, Rajiv, Gane, Edward, Flaherty, John F, Massetto, Benedetta, Gaggar, Anuj, Kitrinos, Kathryn M, Lin, Lanjia, Subramanian, G Mani, McHutchison, John G, Lim, Young-Suk, Acharya, Subrat K, and Agarwal, Kosh

Published
2016
Full Text
View/download PDF

30. P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS

Author

Seto, Wai Kay, primary, Chang, Ting-Tsung, additional, Chowdhry, Abhijit, additional, Chen, Chi-Yi, additional, Celen, Mustafa Kemal, additional, Ma, Xiaoli, additional, Ma, Mang, additional, Duseja, Ajay, additional, Yoon, Ki Tae, additional, Chow, Wan Cheng, additional, Yee, Leland, additional, Weber, Gregor, additional, Youn, Ms Jin, additional, Flaherty, John F., additional, Gaggar, Anuj, additional, Gao, Bing, additional, Camus, Gregory, additional, Bassetti, Eric, additional, Hwang, Jae Seok, additional, Inokuma, Tetshuro, additional, Lin, Young- Suk, additional, and Gane, Edward J., additional

Published
2023
Full Text
View/download PDF

31. Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients

Author

Podlaha, Ondrej, Gane, Edward, Brunetto, Maurizia, Fung, Scott, Chuang, Wan-Long, Pan, Calvin Q., Jiang, Zhaoshi, Liu, Yang, Bhardwaj, Neeru, Mukherjee, Prasenjit, Flaherty, John, Gaggar, Anuj, Subramanian, Mani, Izumi, Namiki, Shalimar, Lim, Young-Suk, Marcellin, Patrick, Buti, Maria, Chan, Henry L. Y., and Agarwal, Kosh

Published
2019
Full Text
View/download PDF

32. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection

Author

Gane, Edward J., Lim, Young-Suk, Gordon, Stuart C., Visvanathan, Kumar, Sicard, Eric, Fedorak, Richard N., Roberts, Stuart, Massetto, Benedetta, Ye, Zhishen, Pflanz, Stefan, Garrison, Kimberly L., Gaggar, Anuj, Mani Subramanian, G., McHutchison, John G., Kottilil, Shyamasundaran, Freilich, Bradley, Coffin, Carla S., Cheng, Wendy, and Kim, Yoon Jun

Published
2015
Full Text
View/download PDF

34. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells

Author

Aggarwal, Abhishek, primary, Odorizzi, Pamela M., additional, Brodbeck, Jens, additional, van Buuren, Nicholas, additional, Moon, Christina, additional, Chang, Silvia, additional, Adona, MaryVic, additional, Suthram, Silpa, additional, Suri, Vithika, additional, Trowe, Torsten, additional, Turner, Scott, additional, Marcellin, Patrick, additional, Buti, Maria, additional, Gaggar, Anuj, additional, Fletcher, Simon P., additional, Diehl, Lauri, additional, Feierbach, Becket, additional, and Balsitis, Scott, additional

Published
2022
Full Text
View/download PDF

35. Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg ‐positive chronic hepatitis B

Author

Wagner, Josef, primary, Yuen, Lilly, additional, Littlejohn, Margaret, additional, Sozzi, Vitina, additional, Jackson, Kathy, additional, Martin, Ross, additional, Aeschbacher, Thomas, additional, Suri, Vithika, additional, Tan, Susanna K., additional, Feierbach, Becket, additional, Gaggar, Anuj, additional, Marcellin, Patrick, additional, Buti Ferret, Maria, additional, Janssen, Harry L. A., additional, Gane, Ed, additional, Meagher, Niamh, additional, Price, David J., additional, Wong, Darren, additional, Thompson, Alexander T., additional, and Revill, Peter A., additional

Published
2022
Full Text
View/download PDF

36. S1189 Safety and Efficacy of Oral TLR8 Agonist, Selgantolimod, in Viremic Adult Patients With Chronic Hepatitis B

Author

Janssen, Harry, primary, Lim, Young-Suk, additional, Kim, Hyung Joon, additional, Tseng, Cheng-Hao, additional, Coffin, Carla, additional, Elkashab, Magdy, additional, Ahn, Sang Hoon, additional, Nguyen, Anh-Hoa, additional, Chen, Diana, additional, Wallin, Jeffrey, additional, Tan, Susana, additional, Yang, Jenny, additional, Gaggar, Anuj, additional, Brainard, Diana, additional, Fung, Scott, additional, Kim, Yoon Jun, additional, Kao, Jia-Horng, additional, Chuang, Wan-Long, additional, Brooks, Anna, additional, and Dunbar, Rod, additional

Published
2022
Full Text
View/download PDF

37. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression

Author

Gane, Edward J., primary, Dunbar, P. Rod, additional, Brooks, Anna E., additional, Zhang, Fangqiu, additional, Chen, Diana, additional, Wallin, Jeffrey J., additional, van Buuren, Nicholas, additional, Arora, Priyanka, additional, Fletcher, Simon P., additional, Tan, Susanna K., additional, Yang, Jenny C., additional, Gaggar, Anuj, additional, Kottilil, Shyamasundaran, additional, and Tang, Lydia, additional

Published
2022
Full Text
View/download PDF

38. Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes

Author

Shah, Samir R., Rao, P. N., Sarin, Shiv K., Chowdhury, Abhijit, Bhatia, Shobna, Dharamsi, Rajesh, Goswami, B. D., Kapoor, Dharmesh, Luaia, Rosang, Mehta, Rajiv, Mukewar, Shrikant, Prasad, V. G. Mohan, Rai, Ramesh Roop, Saigal, Sanjiv, Singh, Devendra, Trehanpati, Nirupama, Chen, Sandra, Gaggar, Anuj, Knox, Steven J., Subramanian, G. Mani, Singh, Shivaram Prasad, Sood, Ajit, Varghese, Joy, and Venugopal, Raj Vigna

Published
2016
Full Text
View/download PDF

40. Quantification of HBV hepatocyte burden using novel multiplex immunofluorescence staining and image analysis reveals substantial reduction in HBV liver burden with anti-viral treatment

Author

Aggarwal, Abhishek, primary, Odorizzi, Pamela, additional, Brodbeck, Jens, additional, Van Buuren, Nicholas, additional, Moon, Christina, additional, Chang, Silvia, additional, Adona, MaryVic, additional, Trowe, Torsten, additional, Turner, Scott, additional, Marcellin, Patrick, additional, Buti, Maria, additional, Gaggar, Anuj, additional, Diehl, Lauri, additional, Feierbach, Becket, additional, and Balsitis, Scott, additional

Published
2022
Full Text
View/download PDF

41. Hepatitis B virus splice variants are associated with reduced likelihood of functional cure and differ across phases of chronic hepatitis B infection

Author

Maslac, Olivia, primary, Wagner, Josef, additional, Sozzi, Vitina, additional, Mason, Hugh, additional, Svarovskaia, Evguenia S, additional, Tan, Susanna, additional, Gaggar, Anuj, additional, Locarnini, Stephen, additional, Yuen, Lilly, additional, Littlejohn, Margaret, additional, and Revill, Peter, additional

Published
2022
Full Text
View/download PDF

43. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B

Author

Bayliss, Julianne, Yuen, Lilly, Rosenberg, Gillian, Wong, Darren, Littlejohn, Margaret, Jackson, Kathleen, Gaggar, Anuj, Kitrinos, Kathryn M, Subramanian, G Mani, Marcellin, Patrick, Buti, Maria, Janssen, Harry L A, Gane, Ed, Sozzi, Vitina, Colledge, Danni, Hammond, Rachel, Edwards, Rosalind, Locarnini, Stephen, Thompson, Alexander, and Revill, Peter A

Published
2017
Full Text
View/download PDF

45. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation

Author

Hsu, Yao-Chun, primary, Suri, Vithika, additional, Nguyen, Mindie H., additional, Huang, Yen-Tsung, additional, Chen, Chi-Yi, additional, Chang, I-Wei, additional, Tseng, Cheng-Hao, additional, Wu, Chun-Ying, additional, Lin, Jaw-Town, additional, Pan, David Z., additional, Gaggar, Anuj, additional, and Podlaha, Ondrej, additional

Published
2022
Full Text
View/download PDF

46. Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg‐positive chronic hepatitis B.

Author

Wagner, Josef, Yuen, Lilly, Littlejohn, Margaret, Sozzi, Vitina, Jackson, Kathy, Martin, Ross, Aeschbacher, Thomas, Suri, Vithika, Tan, Susanna K., Feierbach, Becket, Gaggar, Anuj, Marcellin, Patrick, Buti Ferret, Maria, Janssen, Harry L. A., Gane, Ed, Meagher, Niamh, Price, David J., Wong, Darren, Thompson, Alexander T., and Revill, Peter A.

Subjects
HEPATITIS B virus, HAPLOTYPES, CHRONIC hepatitis B, GENOTYPES
Abstract

Summary: Backgrounds and Aims: We investigated associations between hepatitis B virus (HBV) genome‐length haplotype number (HN) at baseline in subjects with HBeAg‐positive chronic hepatitis B (CHB), and the likelihood of achieving functional cure during direct‐acting antiviral therapy Method: We analysed 86 HBeAg‐positive baseline samples from patients with HBV genotypes A and D who were enrolled in a Phase II trial of tenofovir disoproxil fumarate (TDF) to determine if HN was a biomarker of HBsAg loss during therapy. Findings were validated using baseline samples from 181 patients with HBV genotypes A and D from an independent clinical trial utilising TDF or tenofovir alafenamide therapy in HBeAg‐positive CHB. Results: In the HBeAg‐positive test cohort, patients with genotypes A or D and ≤2 haplotypes had a minimum of 21‐fold higher likelihood of achieving HBsAg loss on TDF. Baseline HN (p < 0.0001) was a stronger predictor of HBsAg loss on therapy than HBsAg titre (p = 0.03), HBeAg titre (p = 0.0002), or the presence of HBV basal core promoter (A1762T, p = 0.0379 and G1764A, p = 0.0176) or G1896A precore mutations (p = 0.0218). This finding was validated in the independent validation cohort. HN was statistically higher in patients with HBV genotypes B or C infection compared to genotypes A and D. Conclusion: Baseline HN ≤2 predicts which patients with HBV genotypes A or D will more likely progress to functional cure on current direct‐acting antiviral therapy, with greater accuracy than current biomarkers including baseline HBsAg and HBeAg titre. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment

Author

Sulkowski, Mark, primary, Telep, Laura E., additional, Colombo, Massimo, additional, Durand, Francois, additional, Reddy, K. Rajender, additional, Lawitz, Eric, additional, Bourlière, Marc, additional, Cheinquer, Nelson, additional, Scherbakovsky, Stacey, additional, Ni, Liyun, additional, Force, Lindsey, additional, Ramroth, Heribert, additional, Gaggar, Anuj, additional, Chokkalingam, Anand P., additional, and Sise, Meghan E., additional

Published
2022
Full Text
View/download PDF

49. Pathogenic CD8 T cells defined by longitudinal liver sampling in chronic hepatitis B patients starting antiviral therapy

Author

Nkongolo, Shirin, primary, Mahamed, Deeqa, additional, Kuipery, Adrian, additional, Sanchez Vasquez, Juan D., additional, Kim, Samuel C., additional, Mehrotra, Aman, additional, Patel, Anjali, additional, Hu, Christine, additional, McGilvray, Ian, additional, Feld, Jordan J., additional, Fung, Scott, additional, Chen, Diana, additional, Wallin, Jeffrey J., additional, Gaggar, Anuj, additional, Janssen, Harry L. A., additional, and Gehring, Adam J., additional

Published
2021
Full Text
View/download PDF

50. Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment

Author

Liu, Chun Jen, primary, Sheen, I Shyan, additional, Chen, Chi Yi, additional, Chuang, Wan Long, additional, Wang, Horng Yuan, additional, Tseng, Kuo Chih, additional, Chang, Ting Tsung, additional, Yang, Jenny, additional, Massetto, Benedetta, additional, Suri, Vithika, additional, Camus, Gregory, additional, Jiang, Deyuan, additional, Zhang, Fangqiu, additional, Gaggar, Anuj, additional, Hu, Tsung Hui, additional, Hsu, Yu Chun, additional, Lo, Gin Ho, additional, Chu, Chi Jen, additional, Chen, Jyh Jou, additional, Peng, Cheng Yuan, additional, Chien, Rong Nan, additional, and Chen, Pei Jer, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results